Skip to Main Content

WASHINGTON — Sen. Bill Cassidy is the rare Republican who has long been open to drug pricing reforms, espousing the virtues of value-based payment arrangements and his home state’s newfangled “Netflix” model for funding hepatitis treatments.

As Cassidy has pushed for reforms, however, the rest of his party’s position on the issue has shifted under his feet, largely thanks to the Trump administration’s unpredictable and aggressive stance on efforts to lower drug costs. President Trump has espoused, for example, a far-reaching proposal to use foreign prices to cap some payments for drugs in the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED